Aptose Biosciences Inc has seen stable price action this week amid significant corporate developments.
Aptose Biosciences Inc (APS.TO) closed today at C$2.40, unchanged from the previous trading session. The stock has not experienced major fluctuations this week, indicating stability as the company moves forward with its acquisition process.
Investor takeaway: Keep an eye on Aptose's upcoming trial results and the completion of its acquisition by Hanmi Pharmaceutical, as these could influence future performance.
Advertisement
Aptose Biosciences Inc
APS.TO
APS.TO
Aptose Biosciences Inc
WealthAwesomeAdvertisement
Market cap
$6.13M
52W high
$2.59
52W low
$1.41
1W change
+0.00%
Beta
0.34
Analyst Price Targets
Based on analyst covering APS
Wall Street analysts forecast APS stock price to fall 1.7% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.36
-1.7% Upside
Current Price
C$2.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APS's historical volatility
30-Day Vol
52.7%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$2.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.40 | C$2.00 – C$2.88 |
| 60 trading days | C$2.40 | C$1.86 – C$3.10 |
| 90 trading days | C$2.40 | C$1.75 – C$3.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
C$2.40: Steady Close Amid Acquisition Developments
Aptose's stock has remained stable at C$2.40, reflecting investor sentiment as the company finalizes its acquisition plans.
Bull case
The acquisition by Hanmi Pharmaceutical could strengthen Aptose's resources and capabilities in drug development, potentially leading to better outcomes in the future.
Bear case
Concerns about the company's long-term viability may arise due to poor financial metrics, including a negative return on equity and low profit margin.
Recent Price Action
Aptose Biosciences Inc closed today at C$2.40, marking no change from the previous day. Over the past week, the stock has shown stability, indicating a consistent trading pattern. Year-to-date, the stock has appreciated by 18.81%, suggesting positive momentum since the beginning of the year.
Catalysts and Company News
Advertisement
No major company news has emerged this week that would impact Aptose's stock price directly. However, the completion of the acquisition by Hanmi Pharmaceutical, set for June 30, 2026, remains a key focus for investors. This acquisition is expected to enhance Aptose's research capabilities and financial support, which may contribute to future growth.
Technical Picture
Aptose's stock is currently trading above its 50-day moving average of C$2.25 and its 200-day moving average of C$2.14, indicating a bullish trend in the medium to long term. The stock has a 52-week trading range of C$1.41 to C$2.59, with its current price at 84% of this range. The stock's beta of 0.34 suggests lower volatility compared to the market, which may appeal to risk-averse investors. Recent trading volume was 2,945 shares, slightly below the 20-day average volume of 3,425 shares.
Insider Activity
No insider activity has been reported this week for Aptose Biosciences Inc, indicating no recent changes in ownership or significant insider transactions.
Price Action Summary
Aptose Biosciences Inc closed at C$2.40 today, reflecting a 1D change of 0.00%. The stock's performance continues to be steady as investors await further developments related to the company's acquisition and clinical trial results.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
